Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker
机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China广东省人民医院[2]Hunan Cancer Hospital, Changsha, China[3]Yunnan Cancer Hospital, Kunming, China[4]The First Affiliated Hospital of Anhui Medical University, Hefei, China[5]Cancer Institute of Northern Jiangsu People's Hospital, Yangzhou, China江苏省人民医院[6]The First Affiliated Hospital of Guangxi Medical University, Nanning, China[7]Army Medical Center of PLA, Chongqing, China[8]The First Hospital of China Medical University, Shenyang, China[9]The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, China[10]The First Hospital of Jilin University, Changchun, China[11]Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[12]Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China广东省中医院[13]Liaoning Cancer Hospital & Institute, Shenyang, China[14]Department of MedicalOncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[15]Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China[16]I-Mab biopharma, Shanghai, China[17]I-Mab Biopharma, Gaithersburg, MD, US.
第一作者机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China
推荐引用方式(GB/T 7714)：
Qing Zhou,Lin Wu,Bo Jiang,et al.Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Qing Zhou,Lin Wu,Bo Jiang,Yingying Du,Buhai Wang...&Yi-Long Wu.(2023).Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Qing Zhou,et al."Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学